Vifor (International) Inc. clinical trials

Acquired by CSL Limited, Aug 9, 2022 · source ↗

The registry lists 10 studies whose lead sponsor is Vifor (International) Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 15, 2025.

Before and after it joined CSL Limited

First submitted before Vifor (International) Inc. became part of CSL Limited: 8
First submitted after Vifor (International) Inc. became part of CSL Limited: 2
Unclear, or no submission date: 0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Completed: 8
Withdrawn: 2

Phase

Phase 2: 3
Phase 1: 1
Phase 4: 1
Phase 3: 1

Where

United Kingdom: 5
Italy: 4
Israel: 3
Lebanon: 3
Spain: 3
United States: 3

Registry sponsor names on this page

Vifor (International) Inc.10 studies

Something wrong with this grouping? Tell us on the CSL Limited page.

Studies

Recruiting first, then most recently updated. Showing 10 of 10. All CSL Limited studies →

RAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT PatientsCompletedNCT05460234
Sponsor listed in the registry: Vifor (International) Inc. · First submitted before Vifor (International) Inc. became part of CSL Limited
Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell DiseaseCompletedNCT04817670Phase 2
Sponsor listed in the registry: Vifor (International) Inc. · First submitted before Vifor (International) Inc. became part of CSL Limited
Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of HyperkalaemiaCompletedNCT04864795
Sponsor listed in the registry: Vifor (International) Inc. · First submitted before Vifor (International) Inc. became part of CSL Limited
Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis PatientsCompletedNCT05524467
Sponsor listed in the registry: Vifor (International) Inc. · First submitted after Vifor (International) Inc. became part of CSL Limited
Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemiaCompletedNCT04364269Phase 2
Sponsor listed in the registry: Vifor (International) Inc. · First submitted before Vifor (International) Inc. became part of CSL Limited
Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Hemodialysis PatientsWithdrawnNCT05625542
Sponsor listed in the registry: Vifor (International) Inc. · First submitted after Vifor (International) Inc. became part of CSL Limited
Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemiaWithdrawnNCT04938635Phase 2
Sponsor listed in the registry: Vifor (International) Inc. · First submitted before Vifor (International) Inc. became part of CSL Limited
Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy SubjectsCompletedNCT05077436Phase 1
Sponsor listed in the registry: Vifor (International) Inc. · First submitted before Vifor (International) Inc. became part of CSL Limited
Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron DeficiencyCompletedNCT02937454Phase 4
Sponsor listed in the registry: Vifor (International) Inc. · First submitted before Vifor (International) Inc. became part of CSL Limited
To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency AnaemiaCompletedNCT03591406Phase 3
Sponsor listed in the registry: Vifor (International) Inc. · First submitted before Vifor (International) Inc. became part of CSL Limited